tbuckley/cabot-search huggingface dataset:
The Supplement Paradox
Authors: Pieter A. Cohen
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-721 Four-Dimensional Analysis Of Mitral Valve Geometry Before And After Percutaneous Edge-to-Edge Mitral Valve Repair
Authors: Thilo Noack, Linda Mallon, Philipp Kiefer, Carmine Bevilaqua, Jörgen Banusch, Fabian Emrich, David M. Holzhey, Joerg Ender, Holger Thiele, Friedrich-Wilhelm Mohr, Joerg Seeburger
Journal: Journal of the American College of Cardiology (2015)
Solving the Problem of Overdiagnosis
Authors: Joann G. Elmore
Journal: New England Journal of Medicine (2016)

My patients’ fear of breast cancer is palpable. I see them fret over whether or not to have a mammogram, worry about false positive abnormalities, and struggle to pay for diagnostic evaluations for which they are not reimbursed. This collateral damage of screening is obvious to clinicians. However, increasing evidence now indicates a less obvious outcome of cancer screening — overdiagnosis of diseases that would never cause symptoms or death. The presence and effects of overdiagnosis are less tangible, buried in population statistics rather than patient encounters.Overdiagnosis of breast cancer has been suggested on the basis of multiple studies . . .
TCT-709 Feasibility of Transapical Implantation of Transcatheter Aortic Valve in the Mitral Position Using a Novel Valve Retention System
Authors: Yanping Cheng, Torsten P. Vahl, Gerard B. Conditt, Adrienne D. Meyers, Karl Van Wygerden, Patricia Mount, Greg L. Kaluza, Juan Granada, Geng-Hua Yi
Journal: Journal of the American College of Cardiology (2015)
ABCA3 Expression in AML Blast Cells: Association with Poor Disease Outcome and Intracellular Drug Sequestration.
Authors: Bjoern Chapuy, Ulf Radunski, Sabrina Corsham, Rafael Koch, Naeun Cheong, Nobuya Inagaki, Frank Griesinger, Dirk Reinhardt, Lorenz Truemper, Gerald G. Wulf
Journal: Blood (2006)
Questions hang over European patent for hepatitis C drug after ruling
Authors: Ned Stafford
Journal: BMJ (2016)

The medical activist group Doctors of the World (Medecins du Monde) is calling for European governments to campaign for the US biotechnology firm Gilead Sciences to lower the price off its effective but very expensive treatment for hepatitis C after the European Patent Office ruled that the current patent must be amended.

The European patent for the blockbuster drug sofosbuvir, which is marketed in Europe as Sovaldi, was issued by the office in May 2014.

In February 2015 Doctors of the World and nine other parties filed “oppositions” requesting “revocation of the patent in its entirety for reasons of non-compliance with legal provisions …
Longitudinal Analysis of Cancer-Testis Antigen Expression in Multiple Myeloma.
Authors: Djordje Atanackovic, Tim Luetkens, Julia Arfsten, Katrin Bartels, York Hildebrandt, Yanran Cao, Christiane Faltz, Christine Wolschke, Axel R. Zander, Carsten Bokemeyer, Nicolaus Kroeger
Journal: Blood (2007)
Cytokine Gene Polymorphisms and Severe Acute Graft-Versus-Host Disease (grade ≥II) After Allogeneic Hematopoietic Stem Cell Transplantation From HLA Identical Siblings
Authors: Valérie Dubois, Mohamad Sobh, Stéphane Morisset, Hélène Labussière-Wallet, Marie Y. Detrait, Sylvie Rey, Isabelle Mollet, Sophie Ducastelle, Fiorenza Barraco, Youcef Chelghoum, Xavier Thomas, Franck E. Nicolini, Mauricette Michallet
Journal: Blood (2012)
HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell Dynamics
Authors: Valentina Gambacorta, Giacomo Oliveira, Laura Zito, Cristina Toffalori, Lara Crucitti, Maddalena Noviello, Benedetta Mazzi, Raffaella Greco, Maria Teresa Lupo Stanghellini, Matteo G Carrabba, Massimo Bernardi, Jacopo Peccatori, Katharina Fleischhauer, Chiara Bonini, Fabio Ciceri, Luca Vago
Journal: Blood (2015)
Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)
Authors: Esther Natalie Oliva, Valeria Santini, Gina Zini, Giuseppe A Palumbo, Antonella Poloni, Agostino Cortelezzi, Maria Teresa Voso, Alfredo Molteni, Grazia Sanpaolo, Antonio Marino, Filippo Rodà, Caterina Alati, Francesca Ronco, Francesco Di Raimondo, Pietro Leoni, Giuliana Alimena, Silvia Finotto, Roberto Latagliata, Francesco Nobile
Journal: Blood (2012)
TCT-327 Calcium Volume Score on Contrast-Enhanced Computed Tomography Prior to Transcatheter Aortic Valve Replacement: what’s the most accurate threshold cutoff?
Authors: Nicolas Bettinger, Nadira Hamid, Susheel Kodali, Rebecca Hahn, Isaac George, Jonathon M. White, Puja B. Parikh, Todd Pulerwitz, Martin Leon, Omar K. Khalique
Journal: Journal of the American College of Cardiology (2015)
Efficacy and Safety of Micafungin, an Echinocandin Antifungal Agent on Systemic Fungal Infections in Patients with Hematological Disorders.
Authors: Kazuo Tamura, Akio Urabe, Minoru Yoshida, Akihisa Kanamaru, Yoshihisa Kodera, Shinichiro Okamoto, Shigefumi Maesaki, Tohru Masaoka
Journal: Blood (2006)
Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells
Authors: Mark A. DeWitt, Wendy Magis, Nicolas L. Bray, Tianjiao Wang, Jennifer R. Berman, Fabrizia Urbinati, Seok-Jin Heo, Therese Mitros, Denise P. Muñoz, Dario Boffelli, Donald B. Kohn, Mark C. Walters, Dana Carroll, David I. K. Martin, Jacob E. Corn
Journal: Science Translational Medicine (2016)

Hematopoietic stem cells from patients with sickle cell disease can be edited by CRISPR/Cas9 and maintain the edits in vivo.
Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression
Authors: Felipe Samaniego, Michelle Fanale, Barbara Pro, F.B. Hagemeister, Peter McLaughlin, Jorge Romaguera, Sattva Neelapu, Maria Alma Rodriguez, Luis Fayad, Anas Younes, Larry W. Kwak
Journal: Blood (2008)
Iron Chelation Therapy with Deferasirox In Transfusion Dependent Myelodysplastic Syndrome Patients. Preliminary Report From the Prospective MDS0306 GIMEMA Trial
Authors: Emanuele Angelucci, Valeria Santini, Anna Angela Di Tucci, Chiara Della Casa, Carlo Finelli, Antonio Volpe, Enrico Maria Pogliani, Giovanni Quarta, Alessandro Levis, Alfonso Maria D'Arco, Giuseppe Saglio, Nicola Cascavilla, Enrica Morra, Daniele Vallisa, Robin Foà, Giuseppe Leone, Sergio Storti, Attilio Gabbas, Luciana Annino, Domenico Magro, Patrizia Tosi, Giovanni Caocci, Pellegrino Musto, Sergio Amadori, Pietro Leoni, Marco Gobbi, Alfonso Piciocchi, Marco Vignetti, Serenella Porcedda, Sante Tura
Journal: Blood (2010)
TCT-627 Left Ventricular Mass Regression After Transcatheter Or Surgical Aortic Valve Replacement: Importance Of Stroke Volume And The Left Ventricular Mass Formula
Authors: Jae K. Oh, Grace Lin, Sahar S. Abdelmoneim, Ana Kadkhodayan, Stephen H. Little, David Adams, Michael J. Reardon, David A. Orsinelli, Jeffrey Popma
Journal: Journal of the American College of Cardiology (2015)
Impact of Activating Killer Immunoglobulin-Receptor Genotype of the Donor on Outcome of Unrelated Donor - Hematopoietic Stem Cell Transplantation.
Authors: Sebastian Giebel, Izabela Nowak, Tomasz Kruzel, Jerzy Wojnar, Miroslaw Markiewicz, Joanna Dziaczkowska, Iwona Wylezol, Malgorzata Krawczyk-Kulis, Renata Bloch, Tomasz Czerw, Agnieszka Karolczyk, Piotr Kusnierczyk, Jerzy Holowiecki
Journal: Blood (2005)
Lenalidomide and Prednisone for Primary and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (MF): An Eastern Cooperative Oncology Group (ECOG) Phase II Trial.
Authors: Ruben A. Mesa, Xiaopan Yao, Larry D. Cripe, Chin Yang Li, Ayalew Tefferi, Martin S. Tallman
Journal: Blood (2008)
Somatic Mosaicism and Variable Expressivity in Diamond Blackfan Anemia (DBA): A Large Deletion Involving the 19q13 Locus in a Patient with Transient Anemia.
Authors: Emanuela Garelli, Paola Quarello, MariaFrancesca Campagnoli, Alfredo Brusco, Adriana Carando, Elisa Menegatti, Nicoletta Crescenzio, Luiselda Foglia, Irma Dianzani, Ugo Ramenghi
Journal: Blood (2005)
P-21 Activated Kinase 1 (Pak1) Is Critical for Normal Mast Cell Degranulation and Cytokine Production in Response to Antigen Stimulation of the High Affinity IgE Receptor.
Authors: Jayme D. Allen, Clemens Hoffman, Ethel Derr-Yellin, Waylan Bessler, Fen-Chun Yang, David A. Ingram, Zahra Jaffer, Amanda Tipton, Johnathan Chernoff, D. Wade Clapp
Journal: Blood (2004)
TCT-217 Efficacy of Dual Antiplatelet Therapy in Women with Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Gennaro Giustino, Usman Baber, Roxana Mehran, Samantha Sartori, Annapoorna Kini, Samin K. Sharma, George Dangas
Journal: Journal of the American College of Cardiology (2015)
Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies.
Authors: Mariaelena Casagrande, Roberto Moretto, Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Beatrice Borelli, Sara Lonardi, Valentina Angela Marsico, Laura Ferrari, Vincenzo Ricci, Roberta Grande, Gianluca Tomasello, Monica Ronzoni, Giacomo Allegrini, Giuseppe Tonini, Maria Laura Mancini, Alberto Zaniboni, Silvana Chiara, Chiara Carlomagno, Alfredo Falcone
Journal: Journal of Clinical Oncology (2016)

e15054 Background: Elderly metastatic colorectal cancer (mCRC) patients (pts) are underrepresented in clinical trials and present heterogeneous physiological and chronological age, general conditions, and comorbidities. Pts between 71 and 75 years old, with ECOG PS 0 were eligible for GONO studies investigating the intensified triple regimen FOLFOXIRI with or without targeted agents as first-line treatment of mCRC. The aim of this analysis was to assess the safety and efficacy of FOLFOXIRI-based regimens in this subpopulation. Methods: Pts between 71 and 75 years old, receiving the triplet with or without targeted agents in GONO-FOLFOXIRI (NCT01219920), FOIB (NCT01163396), TRIP (NCT01358812), TRIBE (NCT00719797), MACBETH (NCT02295930) and MOMA (NCT02271464) studies were identified. Baseline characteristics, safety and efficacy data were reviewed. Results: Out of 784 pts treated with FOLFOXIRI-based regimens, 92 (12%) were ≥ 71 years old, 14 had received FOLFOXIRI, 68 FOLFOXIRI plus bevacizumab and 10 FOLFOXIRI plus cetuximab or panitumumab. Baseline clinical and molecular characteristics were in line with those of the overall population of each trial, except for age (median: 73 years) and a predominance of male gender (67%). No unexpected adverse events or safety issues emerged. Mean relative dose intensities of 5-fluorouracil, oxaliplatin and irinotecan were 73%, 79% and 74%, respectively. Most frequent ( > 5%) grade 3 or 4 adverse events were neutropenia (51%), febrile neutropenia (10%), diarrhea (21%) and thromboembolism (11%). An ORR of 65%, leading to a radical (R0/R1) resection rate of 15% (31% in the liver-limited subgroup) was reported. Median PFS and OS were 10.6 (95%CI 9.9 – 12.5) and 23.7 months (95% CI 20.9 – 28.6), respectively. Conclusions: In mCRC pts between 71 and 75 years old with optimal ECOG PS, FOLFOXIRI-based regimens achieved activity and efficacy results consistent with those reported in the overall population with an acceptable toxicity profile. Based on these results, first-line FOLFOXIRI-based regimens represent a potential option for a subgroup of selected elderly mCRC pts.
Endoscopic resection using the Clutch Cutter and a detachable snare for large pedunculated colonic polyps
Authors: Kazuya Akahoshi, Masaru Kubokawa, Junya Gibo, Shigeki Osada, Kayo Tokumaru, Yuki Shiratsuchi, Masafumi Oya, Eikichi Ihara, Kazuhiko Nakamura
Journal: Endoscopy (2016)

<b>Background and study aims</b> Endoscopic snare polypectomy with prophylactic detachable snare of large pedunculated colonic polyps (PCPs) is technically demanding. To facilitate removal of such polyps, we developed endoscopic resection using the Clutch Cutter and a detachable snare (ERCCDS). This study aimed to evaluate the efficacy and safety of the procedure. <b>Patients and methods</b> From April 2010 to July 2015, 14 consecutive patients who had PCPs with head > 10 mm, stalk width > 5 mm, and stalk length > 10 mm were enrolled in this single-center prospective uncontrolled study. They were treated using ERCCDS by a single endoscopist. The efficacy and safety were assessed using a database prospectively formatted from the medical records. <b>Results</b> The Clutch Cutter was able to cut the distal side of the stalk an adequate distance from the detachable snare under good visual control. R0 resections were obtained in all lesions. There were no immediate or delayed complications. <b>Conclusions</b> ERCCDS appears to be a safe, easy, and technically efficient method for large PCPs, although larger studies are needed to compare ERCCDS and standard resection.
The Response to Repeated Vaccination with PR1 and WT1 Peptides Admixed in Montanide Adjuvant Is Transient and Fails to Induce Sustained Anti-Leukemia Responses in Patients with Myeloid Malignancies.
Authors: Katayoun Rezvani, Agnes S. M. Yong, Stephan Mielke, Behnam Jafarpour, Bipin N. Savani, Quan Le, Rhoda Eniafe, Carol Boss, Roger J Kurlander, A. John Barrett
Journal: Blood (2009)
TCT-650 Efficacy of a 1-year follow-up program conducted in a tertiary care centre following percutaneous aortic valve implantation: the TAVI follow-up program
Authors: Tiziana Claudia Aranzulla, Mauro De Benedictis, Innocenzo Scrocca, Barbara Mabritto, Alfredo Pizzuti, Emanuele Meliga, Maria Elena Rovere, Maria Rosa Conte
Journal: Journal of the American College of Cardiology (2015)
Targeted Therapy in CMML: Complete Molecular Response to Sorafenib in a Patient with a FLT3-ITD Malignant Hematopoiesis
Authors: Olivier Kosmider, Nicolas Chapuis, Sophie Kaltenbach, Romain Coriat, Pascaline boudou-Rouquette, Lise Willems, Virginie Chesnais, Isabelle Radford-Weiss, Valérie Bardet, Patrick Mayeux, Jerome Tamburini, Michaela Fontenay, Didier Bouscary
Journal: Blood (2012)
Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.
Authors: Eyal C. Attar, Kati Maharry, Krzysztof Mrózek, Michael D. Radmacher, Susan P. Whitman, Peter Paschka, Christian Langer, Kelsi B. Holland, Bayard L. Powell, Jonathan E. Kolitz, Andrew J. Carroll, Richard A. Larson, Guido Marcucci, Clara D. Bloomfield
Journal: Blood (2009)
Heterogeneous Chromosomal Mechanisms Generating the 5′RUNX1/3′CBFA2T1 Gene in Acute Myeloid Leukemia.
Authors: Giorgina Specchia, Francesco Albano, Luisa Anelli, Antonella Zagaria, Arcangelo Liso, Roberta La Starza, Marco Mancini, Antonio Cuneo, Giuseppe Saglio, Paola Fazi, Nicoletta Testoni, Laura Vicari, Vincenzo Liso, Mariano Rocchi
Journal: Blood (2004)
TCT-158 Fully Percutaneous Transthoracic Left Atrial Entry and Closure to Deliver Large Caliber Transcatheter Mitral Valve Implants
Authors: Toby Rogers, Kanishka Ratnayaka, William H. Schenke, Merdim Sonmez, Ozgur Kocaturk, Jonathan R. Mazal, Marcus Y. Chen, Anthony Z. Faranesh, Robert J. Lederman
Journal: Journal of the American College of Cardiology (2015)
A Distinctive Pattern of Different Gene Expression in Chronic Myelogenous Leukemia Patients
Authors: Carla Di Stefano, Marco Tafani, Bruna Pucci, Elisabetta Abruzzese, Margherita Trawiska, Manuela Indelicato, Margherita Trawiska, Paola Sinibaldi-Salimei, matteo Antonio Russo, Sergio Amadori, Gabriella Marfe
Journal: Blood (2008)
Isocitrate dehydrogenase mutations in myeloid malignancies
Authors: B C Medeiros, A T Fathi, C D DiNardo, D A Pollyea, S M Chan, R Swords
Journal: Leukemia (2016)

Alterations to genes involved in cellular metabolism and epigenetic regulation are implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate dehydrogenase (IDH) genes are detected in approximately 20% of adult patients with acute myeloid leukemia (AML) and 5% of adults with myelodysplastic syndromes (MDS). IDH proteins are homodimeric enzymes involved in diverse cellular processes, including adaptation to hypoxia, histone demethylation and DNA modification. The IDH2 protein is localized in the mitochondria and is a critical component of the tricarboxylic acid (also called the 'citric acid' or Krebs) cycle. Both IDH2 and IDH1 (localized in the cytoplasm) proteins catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG). Mutant IDH enzymes have neomorphic activity and catalyze reduction of α-KG to the (R) enantiomer of 2-hydroxyglutarate, which is associated with DNA and histone hypermethylation, altered gene expression and blocked differentiation of hematopoietic progenitor cells. The prognostic significance of mutant IDH (mIDH) is controversial but appears to be influenced by co-mutational status and the specific location of the mutation (IDH1-R132, IDH2-R140, IDH2-R172). Treatments specifically or indirectly targeted to mIDH are currently under clinical investigation; these therapies have been generally well tolerated and, when used as single agents, have shown promise for inducing responses in some mIDH patients when used as first-line treatment or in relapsed or refractory AML or MDS. Use of mIDH inhibitors in combination with drugs with non-overlapping mechanisms of action is especially promising, as such regimens may address the clonal heterogeneity and the multifactorial pathogenic processes involved in mIDH myeloid malignancies. Advances in mutational analysis have made testing more rapid and convenient, and less expensive; such testing should become part of routine diagnostic workup and repeated at relapse to identify patients who may benefit from treatments that target mIDH.
TCT-662 Prognostic Importance Of Pulmonary Hypertension Etiology By Invasive Hemodynamics In Patients With Severe Aortic Stenosis
Authors: Joao L. Cavalcante, Andrew Althouse, Ryan Massa, Mitika Maddula, William Katz, Frederick Crock, Matthew E. Harinstein, Forozan Navid, Dustin Kliner, John T. Schindler, Thomas Gleason, Joon S. Lee
Journal: Journal of the American College of Cardiology (2015)
STAT3 Is Constitutively Phosphorylated on Serine 727 Residues, Activates Transcription, and Plays a Major Role in the Pathogenesis of B-Cell Chronic Lymphocytic Leukemia.
Authors: Inbal Hazan-Halevy, David Harris, Zhiming Liu, Alessandra Ferrajoli, Michael J Keating, Zeev Estrov
Journal: Blood (2008)
A 17q25.3 Duplication Defines a New Dosage-Sensitive Congenital Neutropenia Locus and Implicates SOCS3 as a Candidate Gene for Cases Unexplained by ELA2 Mutation.
Authors: Matthew E. Mealiffe, Doan Le, Zhijun Duan, Helen Papadaki, George Eliopoulos, Raffaele Badolato, Marshall S. Horwitz
Journal: Blood (2006)
Initial experience of concurrent chemoradiotherapy for unresectable pancreatic cancer using gemcitabine via intravenous and trans-arterial infusion
Authors: N. Uchida, M. Notani, N. Yamamoto, J. Ishida, J. Yoshigi, H. Kitagaki, Y. Nio, S. Yano, M. Itakura
Journal: Journal of Clinical Oncology (2005)

4273 Background: Intra-arterial infusion chemotherapy can deliver higher concentrations to the primary tumor, with potentially greater efficacy and less toxicity. Purpose of this study was to retrospectively evaluate the efficacy and toxicity of concurrent chemoradiotherapy using gemcitabine via trans-arterial and intravenous infusion for patients with unresectable pancreatic cancer Methods: Five patients (male,4; female,1; ages, 49–72) with unresectable pancreatic cancer (stage III, 3; stage IV,2) received concurrent chemoradiotherapy between January 2002 and June 2004. All patients received selective arterial infusion chemotherapy through arterial port implantated transcutaneously; mean total dosage of gemcitabine was 740mg and with a mean of 3.2 treatment courses. Patients received concurrent radiotherapy (mean dose 51.2Gy, range 50.0 to 55.6Gy in 25 to 31 fractions) from a linear accelerator, to the primary tumor and regional lymphatics by four portal or rotation method. Three received concurrent systemic gemicitabine chemotherapy in bio-weekly cycles (200mg/body). Initial clinical response and frequency of acute toxicity according to CTCAE ver.3 were evaluated. Kaplan-Meier analysis was used to calculate local control (LC), and overall survival (OS). Median observation time was 6.9 months. Results: Initial local response was CR:0, PR:1, SD:4, and response rate (CR+PR) was 20%. No patient’s acute toxicity was worse than grade 3 leukocytopenia, thrombocytopenia or gastrointestinal toxicity. Three patients had grade 2 leukocytopenia. No patients had acute or late complications relating to the implanted arterial port such as arterial thrombosis, pancreatitis, abscess formation. There was no break or termination of the radiation treatment course. Median LC duration and OS duration was 144 days. Conclusions: Trans-arterial and systemic infusion of gemicitabine combined with radiotherapy appears to be a feasible and safe regimen which may offer beneficial results for unresectable pancreatic cancer patients. No significant financial relationships to disclose.
GW27-e0188 Hrimary hyperaldosteronism complicated by renal cancer: report of a case andliterature review
Authors: Zhenhua Huang, Hong Zhan, Xiaoyong Xiao, Zi Ye, Peng Jiang, Zhihao Liu, Feng Zhu, Wanwan Zhang, Yan Xiong, Yingxiong Huang, Jinli Liao
Journal: Journal of the American College of Cardiology (2016)
Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.
Authors: Gudrun Göhring, Aristoteles Giagounidis, Guntram Büsche, Hans Kreipe, Martin Zimmermann, Eva Hellstrom-Lindberg, Carlo Aul, Brigitte Schlegelberger
Journal: Blood (2009)
TCT-80 Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: Qualitative optical coherence tomographic analysis
Authors: Ji-Yong Jang, Jung-Sun Kim, Dong-Ho Shin, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong
Journal: Journal of the American College of Cardiology (2015)
MIC A/B Protein Expression Associates with Trastuzumab-Resistant Breast Cancer Cells Leading to Effective Immunotherapy by Cytokine Induced Killer Cells.
Authors: Dario Sangiolo, Giorgio Valabrega, Giuliana Cavalloni, Sonia Capellero, Giulia Mesiano, Maja Todorovic, Cristina Cammarata, Caterina Peraldo Neia, Wanda Piacibello, Alessandro Cignetti, Massimo Aglietta
Journal: Blood (2009)